Breaking Finance News

TheStreet upgraded Phibro Animal Health Corp (NASDAQ:PAHC) to Hold in a report released today.

TheStreet has upgraded Phibro Animal Health Corp(NASDAQ:PAHC) to Hold in a report released on Wednesday September 14 2016.

Showing a price of $26.32, Phibro Animal Health Corp (NASDAQ:PAHC) traded 1.74% higher on the day. With the last stock close up 19.34% from the 200-day average, compared with the S&P 500 which has fallen -0.01% over the same period. Phibro Animal Health Corp has been tracking to a 50-day average of $22.56 and 200-day moving average of $22.06. Trade volume was was down over the average, with 88,056 shares of PAHC changing hands under the typical 146,436 shares.

Recent Performance Chart:

Phibro Animal Health Corp (NASDAQ:PAHC)

Phibro Animal Health Corp has a 52 week low of $16.80 and a one-year high of $36.99 with a P/E ratio of 13 and has a market cap of $0.0.

Also covering Phibro Animal Health Corp’s stock price target, a total of 5 firms have issued a ratings update on the company. The consensus target stock price is $35.00 with 0 rating the company a strong buy, 0 rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 firmsrating the company as sell.

Brief Synopsis On Phibro Animal Health Corp (NASDAQ:PAHC)

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. The Company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. The Company’s Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company’s MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, and Coxistac and amprolium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.